biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Purchases 43,378 Shares

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc purchased 43,378 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average cost of $3.15 per share, with a total value of $136,640.70. Following the completion of the acquisition, the insider now directly owns 4,107,987 shares of the company’s stock, valued at $12,940,159.05. The trade was a 1.07 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Thursday, April 3rd, Guines Llc acquired 7,321 shares of biote stock. The stock was bought at an average price of $3.24 per share, with a total value of $23,720.04.
• On Monday, March 31st, Guines Llc bought 106,000 shares of biote stock. The shares were bought at an average price of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc acquired 100 shares of biote stock. The stock was bought at an average price of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The stock was purchased at an average price of $3.22 per share, for a total transaction of $2,415,000.00.

biote Stock Performance

Shares of NASDAQ BTMD opened at $3.25 on Wednesday. biote Corp. has a 1 year low of $3.04 and a 1 year high of $8.44. The firm’s 50-day moving average is $4.20 and its 200-day moving average is $5.25. The firm has a market capitalization of $177.81 million, a PE ratio of 12.50 and a beta of 1.17.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum cut their price target on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Hedge Funds Weigh In On biote

A number of hedge funds and other institutional investors have recently bought and sold shares of BTMD. Price T Rowe Associates Inc. MD acquired a new position in shares of biote in the 4th quarter valued at $67,000. Commonwealth Equity Services LLC acquired a new position in biote in the fourth quarter valued at about $68,000. Public Employees Retirement System of Ohio bought a new position in biote during the fourth quarter worth about $69,000. Intech Investment Management LLC acquired a new position in shares of biote during the 4th quarter worth about $71,000. Finally, SG Americas Securities LLC bought a new stake in shares of biote in the 4th quarter valued at about $76,000. 21.68% of the stock is owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.